Medical condition
Pancreatic Cancer
Pancreatic Cancer is a medical condition tracked by NovaPharmaNews across 3 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- pancreas powder (ENZEPI) Alimentary tract and metabolism (A09)
- masitinib (MASITINIB AB SCIENCE) Antineoplastic and immunomodulating agents (L01)
- erlotinib (ERLOTINIB ARX) Antineoplastic and immunomodulating agents (L01)
Latest Pancreatic Cancer news
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.
Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know
Daraxonrasib, a first-in-class RAS inhibitor, nearly doubled overall survival in a Phase III trial for advanced pancreatic cancer. The data marks a potential shift in treatment paradigms for one of the deadliest cancers.
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
Revolution Medicines’ daraxonrasib nearly doubled median survival in a Phase 3 trial for pancreatic cancer, offering a new standard of care. This article analyzes the clinical data, side effect profile, and competitive implications for pharma teams.
Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access
Revolution Medicines' daraxonrasib has shown a dramatic overall survival benefit in pancreatic cancer, but patient demand is overwhelming the expanded access program. For pharma strategists, the supply-demand imbalance signals potential launch revenue upside and commercial execution risk.
Experimental pancreatic cancer drug offers new hope in major trial
Structured plan for Experimental pancreatic cancer drug offers new hope in major trial
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Structured plan for FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Revolution Medicines' Pancreatic Cancer Drug: Practice-Changing Results
Revolution Medicines has reported groundbreaking results for its pancreatic cancer drug, potentially transforming treatment protocols. This article explores the implications for the pharmaceutical industry.